BG Medicine Welcomes Inclusion of Galectin-3 as Biomarker of Myocardial Fibrosis in 2013 ACCF/AHA Guideline for Management of

BG Medicine Welcomes Inclusion of Galectin-3 as Biomarker of Myocardial
Fibrosis in 2013 ACCF/AHA Guideline for Management of Heart Failure

Galectin-3 Cited as an Emerging Biomarker for Risk Prediction in Patients With
Heart Failure

WALTHAM, Mass., June 12, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD) announced today that galectin-3 testing has been recognized for
the first time in the newly issued 2013 American College of Cardiology
Foundation and the American Heart Association (ACCF/AHA) Guideline for the
Management of Heart Failure. The ACCF/AHA Guideline is designed to assist
clinicians in selecting the best management strategy for individual patients
and provides expert analysis of data on prevention, diagnosis, risk
stratification, and treatment.

Galectin-3 testing has been assigned a Level of Evidence of 'A', multiple
populations evaluated, and a Class of Recommendation corresponding to 'May Be
Considered' for the purpose of additive risk stratification of acute heart
failure patients, and a Level of Evidence of 'B', limited populations
evaluated, and a Class of Recommendation of 'May Be Considered' for risk
stratification of ambulatory heart failure patients.

The guideline further notes that testing for galectin-3 is predictive of risk
of adverse outcomes in heart failure, including hospitalization, and is
additive to BNP and NT-proBNP testing for heart failure patient risk
stratification.

"We believe that the inclusion of galectin-3 in the updated ACCF/AHA Guideline
is an important recognition of the potential significance of galectin-3 in the
evaluation and management of patients with heart failure," commented Paul
Sohmer, M.D., President and Chief Executive Officer of BG Medicine.

About American College of Cardiology Foundation and the American Heart
Association (ACCF/AHA) Guideline for the Management of Heart Failure

The American College of Cardiology Foundation (ACCF) and the American Heart
Association (AHA) have jointly produced guidelines in the area of
cardiovascular disease since 1980. The ACCF/AHA Task Force on Practice
Guidelines is charged with developing, updating and revising practice
guidelines for cardiovascular diseases and procedures.Writing committees are
charged with regularly reviewing and evaluating all available evidence to
develop balanced, patient-centric recommendations for clinical practice.The
guidelines for heart failure management were last published in 2009.

The 2013 ACCF/AHA Guideline for the Management of Heart Failure is currently
available online at
http://circ.ahajournals.org/content/early/2013/06/03/CIR.0b013e31829e8807 and
will be published in the August 27, 2013 print issue of theJournal of the
American College of Cardiology (JACC).

About Galectin-3 Testing

Galectin-3 has been implicated in a variety of biological processes important
in the development and progression of heart failure. Higher levels of
galectin-3 are associated with a more aggressive form of heart failure, which
may make identification of high-risk patients using galectin-3 testing an
important part of patient care. Galectin-3 testing may be useful in helping
physicians determine which patients are at higher risk of death or
hospitalization, including 30-day readmission.www.galectin-3.com

AboutBG Medicine, Inc.

BG Medicine, Inc.(Nasdaq:BGMD) is a diagnostics company focused on the
development and commercialization of novel cardiovascular tests to address
significant unmet medical needs, improve patient outcomes and reduce
healthcare costs.For additional information aboutBG Medicine, heart failure
and galectin-3 testing, please
visitwww.bg-medicine.comandwww.galectin-3.com.

TheBG Medicine Inc.logo is available for downloadhere

Forward Looking Statements

Certain statements made in this news release contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of 1934, as
amended, that are intended to be covered by the "safe harbor" created by those
sections. Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can generally be
identified by the use of forward-looking terms such as "believe," "expect,"
"may," "will," "should," "could," "seek," "intend," "plan," "estimate,"
"anticipate" or other comparable terms. Forward-looking statements in this
news release address our belief that the inclusion of galectin-3 in the
updated ACCF/AHA Guideline is an important recognition of the potential
significance of galectin-3 in the evaluation and management of patients with
heart failure; our understanding that higher levels of galectin-3 are
associated with a more aggressive form of heart failure, which may make
identification of high-risk patients using galectin-3 testing an important
part of patient care; and our belief that galectin-3 testing may be useful in
helping physicians determine which patients are at high risk of cardiovascular
death or rehospitalization, including 30-day readmission. Forward-looking
statements are based on management's current expectations and involve inherent
risks and uncertainties which could cause actual results to differ materially
from those in the forward-looking statements, as a result of various factors
including those risks and uncertainties described in the Risk Factors and in
Management's Discussion and Analysis of Financial Condition and Results of
Operations sections of our recent filings with the Securities and Exchange
Commission, including our most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q. We urge you to consider those risks and uncertainties in
evaluating our forward-looking statements. We caution readers not to place
undue reliance upon any such forward-looking statements, which speak only as
of the date made. Except as otherwise required by the federal securities laws,
we disclaim any obligation or undertaking to publicly release any updates or
revisions to any forward-looking statement contained herein (or elsewhere) to
reflect any change in our expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based

CONTACT: Media Contacts:
         For BG-Medicine: 
         Chris Erdman, MacDougall Biomedical Communications,(781) 235-3060

         BG-Medicine Investor Inquiries:
         Chuck Abdalian, EVP & Chief Financial Officer, (781) 434-0210

BG Medicine Inc. logo
 
Press spacebar to pause and continue. Press esc to stop.